Shandong Pharmaceutical Glass Co., Ltd.

Shandong Pharmaceutical Glass Co., Ltd. has seen a significant decline in its stock performance, with notable decreases over various time frames. Recent financial metrics reveal challenges, including a drop in net sales and a modest return on equity, as the company faces a tough market environment.

Shandong Pharmaceutical Glass Co., Ltd. saw a 3.2% decline in stock price, contrasting with the broader market's performance. The company has experienced volatility, with a slight weekly decrease and a monthly gain. Long-term trends show significant declines, raising concerns amid challenges in net sales and market dynamics.

Shandong Pharmaceutical Glass Co., Ltd. saw a significant intraday increase on May 29, 2026, contrasting with a decline in the China Shanghai Composite. Despite recent gains, the company faces long-term challenges, including a year-over-year decline in performance and a notable drop in net sales, indicating a complex financial situation.

Shandong Pharmaceutical Glass Co., Ltd. saw a significant stock decline today, contrasting with a slight increase in the China Shanghai Composite. The company has faced challenges, including a drop in net sales and a weak long-term performance, with notable declines over the past month and year in a competitive market.

Shandong Pharmaceutical Glass Co., Ltd. saw a significant intraday increase on May 25, 2026, contrasting with the broader market's performance. Despite recent gains, the company faces long-term challenges, including a decline in annual performance and net sales. Its financial metrics indicate potential for improved profitability.

Shandong Pharmaceutical Glass Co., Ltd. saw a significant rise in its stock today, reaching an intraday high. The company has outperformed the China Shanghai Composite recently, although it faces longer-term challenges with notable declines over the past year and five years. Its market capitalization stands at CNY 11,733 million.

Shandong Pharmaceutical Glass Co., Ltd. has undergone a recent evaluation adjustment, reflecting a cautious outlook due to its technical score. The company's performance indicators, including MACD and Bollinger Bands, suggest a challenging environment, compounded by a decline in net sales and modest growth rates over the past five years.